The Vascular Clock

The most important cardiovascular signal your doctor might not have mentioned

THE SIGNATURE CHAPTER

The Opening: The Sentinel Event

In medicine, we have a concept called the sentinel event — a signal that arrives before the major event, warning you that the system is under stress. In hospital quality management, the sentinel event is the near-miss, the adverse outcome that carries advance notice of the systemic failure that produced it. In individual physiology, the sentinel event is the early warning — the body sending the most honest message it can in the language available to it.

The penile artery is approximately 1 to 2 millimeters in diameter. The coronary artery that supplies the front wall of the heart muscle — the left anterior descending artery, whose occlusion cardiologists call the “widow-maker” — is 3 to 4 millimeters in diameter. The carotid artery is 5 to 7 millimeters. The femoral artery is 6 to 8 millimeters.

Endothelial dysfunction — the early process by which the inner lining of your arteries loses its ability to dilate properly, to produce nitric oxide on demand, to maintain the anti-inflammatory, anti-thrombotic, vasodilatory environment that keeps arteries healthy — does not affect all arteries simultaneously. It progresses through the vascular tree in a pattern determined, in part, by the diameter of the vessels involved. Smaller arteries reach the point of hemodynamically significant dysfunction earlier in the atherosclerotic process than larger ones. The same plaque burden that is still subclinical in the coronary circulation has already produced a clinically symptomatic functional deficit in the penile circulation.

This is the artery-size hypothesis, formalized by the Italian cardiologist Francesco Montorsi and colleagues in 2006. It is the anatomical basis for the most important clinical statement in this chapter: in two-thirds of men with erectile dysfunction who are later found to have coronary artery disease, the ED came first — on average, by two to five years. Sometimes longer.

In the language of cardiology, erectile dysfunction in a man under sixty is not a sexual problem. It is a vascular problem wearing a sexual disguise. And the man who treats the disguise without investigating the problem is, in a strictly clinical sense, missing his best opportunity.

The artery-size hypothesis is elegant. The evidence supporting it is robust. And the clinical opportunity it creates — a window of two to five years in which the signal has arrived but the major event has not — is one of the most actionable findings in preventive cardiology. Your penis is not malfunctioning. It is doing exactly what a small-artery vascular system does when endothelial dysfunction is progressing: it reports the problem first.

The Endothelial Dysfunction Mechanism

The endothelium is the single-cell monolayer that lines every blood vessel in your body — 10 trillion cells covering a total surface area roughly equivalent to a football field. It is not passive anatomical lining. It is an active endocrine organ that continuously regulates vascular tone, prevents clot formation, suppresses inflammation, and coordinates the blood vessel’s response to the demands placed on it.

In health, when a vessel needs to dilate — because exercise increases demand, or because a nerve signal requires more blood flow to a specific tissue — endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO). Nitric oxide diffuses to the underlying smooth muscle layer, causing relaxation and vasodilation. This is the mechanism by which erectile tissue fills with blood. NO-mediated smooth muscle relaxation allows the cavernous bodies of the penis to expand, restricts venous outflow, and produces erection. The whole process is fundamentally a vascular event driven by nitric oxide bioavailability.

Endothelial dysfunction is defined as impaired nitric oxide bioavailability — reduced production, increased destruction, or both — combined with a shift toward a pro-inflammatory, pro-thrombotic state. Its causes are well-established: hypertension, dyslipidemia, hyperglycemia, insulin resistance, chronic cortisol elevation, smoking, oxidative stress from multiple sources. These are exactly the inputs produced by the upstream processes described in Chapters 1 and 2: the chronic HPA activation, the allostatic load, the metabolic consequences of years of chronic stress.

When endothelial dysfunction is present, the smooth muscle of the penile vasculature cannot relax fully. Blood flow is insufficient. The erectile response is impaired. The signal is clear. And it is, if you are paying attention, the earliest measurable report on the state of your vascular endothelium that your body knows how to produce.

The clinical gold standard for measuring endothelial function non-invasively is flow-mediated dilation (FMD) of the brachial artery — a technique measuring how well the brachial artery dilates in response to increased blood flow. A landmark 2018 study in the Journal of the American Heart Association, the FMD-J study by Maruhashi and colleagues, found that FMD below 7.1% independently predicted future coronary events with a hazard ratio of 0.27 for those above that threshold — meaning the brachial artery response is a real and significant predictor of what is happening in the coronary circulation. The same endothelial dysfunction that impairs the FMD response impairs the penile vascular response. These are manifestations of the same systemic process.

The 59% Number: The Meta-Analysis That Should Change Practice

In 2013, Charalambos Vlachopoulos and colleagues published a systematic review and meta-analysis in the European Heart Journal that has become the foundational reference document for the cardiovascular significance of erectile dysfunction. They pooled data from prospective cohort studies — not case reports, not cross-sectional surveys, but prospective studies following men over time — and found the following associations between erectile dysfunction and subsequent cardiovascular events (Vlachopoulos et al. 2013, DOI: 10.1093/eurheartj/eht112):

• Incident cardiovascular events: HR 1.47 (95% CI 1.21–1.79)
• Coronary heart disease: HR 1.62 (95% CI 1.21–2.16)
• Stroke: HR 1.39 (95% CI 1.11–1.75)
• All-cause mortality: HR 1.25 (95% CI 1.12–1.40)

The word “independently” in these findings means that after statistical adjustment for age, smoking, hypertension, diabetes, and cholesterol, the association between erectile dysfunction and cardiovascular events remains. The ED is not simply a marker of other risk factors — it has independent predictive value. A different analysis from a large systematic review by Gandaglia and colleagues in European Urology found that ED increased risk of ischemic heart disease by 59% and stroke by 34% (Gandaglia et al. 2014, DOI: 10.1016/j.eururo.2013.08.023).

To put those numbers in clinical context: ED as a cardiovascular risk enhancer has an effect size comparable to smoking in men under sixty. Smoking is a cardiovascular risk factor that every physician asks about, every clinical guideline includes, and every patient is counseled on at virtually every clinical encounter. Erectile dysfunction — which is easier to assess, easier to discuss in clinical terms once you have the language, and which carries as strong a predictive signal as smoking in the age range where it matters most — is asked about in a fraction of clinical encounters.

The evidence is strong. The clinical uptake is not proportional to the evidence. That gap is part of what this chapter exists to address.

The Two-to-Five Year Window: The Intervention Opportunity

The Epidemiology: How Common, How Concealed

Before I continue with the mechanism, I want to pause on the prevalence data, because one of the most consistent findings in the clinical literature on erectile dysfunction is the gap between how common it is and how rarely it is discussed.

Studies using validated assessment instruments estimate that erectile dysfunction affects approximately 40 to 45% of men over the age of forty in the United States. In men between forty-four and fifty-five — the core of the population this book addresses — prevalence studies consistently find rates in the 30 to 45% range depending on the severity threshold used. By sixty, the prevalence exceeds 50% for at least mild dysfunction. These are not fringe numbers. Erectile dysfunction in midlife is more common than hypertension among men under fifty.

Yet from the Cleveland Clinic MENtion It research: only 30% of men will seek help for sexual dysfunction. Forty-three percent of men would not discuss frequent erectile dysfunction even with their partner.

The gap between prevalence and disclosure is not primarily about access or awareness. It is about the shame taxonomy I described in the psychographic research underlying this book. Erectile dysfunction sits at the deepest node of the male shame map — further from disclosure than depression, than anxiety, than weight gain, than financial fear. It is experienced as a direct threat to core masculine identity in a way that no other symptom is. A man with hypertension can accommodate that finding into a narrative of managing his health. A man with erectile dysfunction has difficulty constructing an equivalent accommodation because the symptom is framed — by culture, by advertising, by the particular silence men maintain about sexual function with one another — as something closer to a verdict about who he is.

The cardiovascular consequence of this shame architecture is that the sentinel event goes unreported for years. Clinicians don’t ask. Men don’t tell. The two-to-five year window that the Inman data describes as an intervention opportunity is consumed in silence.

This is worth naming directly: the shame attached to erectile dysfunction is not a personal failing. It is a culturally constructed response to a physiological finding that happens to occupy the most loaded territory in male identity. Recognizing that the shame is constructed — that it is not inherent to the finding — is the first step toward having the clinical conversation that the finding warrants.

The PDE5 Inhibitor and What It Does and Doesn’t Tell You

A significant proportion of men reading this chapter are already taking or have taken a PDE5 inhibitor — sildenafil, tadalafil, avanafil, or similar — and have found it effective. I want to address what that effectiveness does and does not mean.

PDE5 inhibitors work by blocking phosphodiesterase type 5, the enzyme that degrades cGMP — the intracellular messenger produced in response to nitric oxide stimulation. By preventing cGMP breakdown, these medications prolong the effect of whatever nitric oxide the endothelium produces, facilitating smooth muscle relaxation and blood flow. They are pharmacological amplifiers of the endothelial NO signal.

Their effectiveness does not mean the underlying endothelial dysfunction is resolved. A man who takes tadalafil and achieves adequate erectile function is experiencing a drug-mediated compensation for an impaired physiological process. The endothelial dysfunction continues. The atherogenic process it reflects continues. The coronary arteries are not improved by the tadalafil. The ApoB is not addressed by the tadalafil. The CAC score is accumulating while the tadalafil does its work in the penile circulation.

This is not a criticism of PDE5 inhibitors. They are genuinely effective medications, they are safe for most patients, and the Princeton IV Consensus notes emerging evidence that they may have some vasculoprotective effects in their own right. The point is narrower: the presence of effective pharmaceutical treatment for the sexual symptom does not close the cardiovascular question. The man who has been on tadalafil for eighteen months and has not had a cardiovascular evaluation is a man who has managed the presentation of the sentinel event without investigating the underlying signal.

The clinical imperative is not to stop the PDE5 inhibitor. It is to add the cardiovascular evaluation.

The Olmsted County cohort study by Inman and colleagues followed 1,402 men in Rochester, Minnesota over ten years. They found that erectile dysfunction preceded incident coronary artery disease by a mean of 3.3 years across the full cohort. In men between the ages of 40 and 49 — the age range in which the ED-CAD signal is strongest — the hazard ratio for incident coronary artery disease in those who developed ED was 5.0 (95% CI 1.5–16.5) (Inman et al. 2009, PMC2664580).

Five-fold. In men under fifty. After adjusting for traditional cardiovascular risk factors.

The clinical significance of this finding is not primarily statistical. It is temporal. Two to five years is a meaningful preventive window. It is the difference between identifying vascular risk before coronary stenosis is established and identifying it after. It is the difference between a preventive cardiology conversation and an emergency department conversation.

The Princeton IV Consensus, the most current and comprehensive multi-specialty guidelines on the management of erectile dysfunction and cardiovascular disease — updated by Köhler and colleagues in Mayo Clinic Proceedings in 2024 — now explicitly recommends that men with ED who are otherwise at low to intermediate 10-year cardiovascular risk should be considered for coronary artery calcium scoring as a next step in risk stratification (Köhler et al. / Princeton IV, DOI: 10.1016/j.mayocp.2024.06.002). Not as a distant option. As a standard next step.

The man with erectile dysfunction is not sitting with a sexual problem. He is sitting with a cardiovascular sentinel event and a two-to-five year window to act before the coronary arteries begin telling their own version of the same story.

The Things Men Attribute It To

Before I go further into the mechanism, I want to spend some time with the taxonomy of the acceptable explanation — the set of attributions that men use, reliably, when they notice changes in erectile function and translate them into something that does not require a physician appointment.

Stress. The most common attribution, and the most clinically misleading. Not because stress has no effect — it does, through the cortisol-testosterone axis described in Chapter 4 — but because “stress” as an explanation closes the conversation in the same moment it opens it. Once the attribution is made, the conversation is over. The man who says to himself “it’s just stress” has simultaneously identified a real factor and used it to prevent further investigation.

Age. The second most common, and the most dangerous in men under sixty, because it is partially true and used as a complete explanation. Age-related decline in erectile function is real — it follows a documented trajectory that begins around forty and continues through the decades. But age is not destiny, and age-related decline is not the same as vascular-origin dysfunction. The key clinical distinction is the pattern of onset: gradual, progressive erectile dysfunction that began in the mid-forties, is not situationally variable, and is associated with other cardiovascular risk signals is a different finding than situational dysfunction in an otherwise well-perfused vascular system.

Drinking. Alcohol has acute effects on erectile function, and many men have experience of this. The attribution to drinking works when the pattern is episodic. When it has become the explanation for a change that has been progressive over two years, the attribution has exceeded the explanatory capacity of the cause.

Too tired. True, and clinically incomplete. Fatigue from disrupted sleep architecture — itself a marker of HPA overactivation, potential obstructive sleep apnea, and declining slow-wave sleep with its associated testosterone consequences — impairs erectile function through multiple mechanisms. The fatigue is not incidental. It is part of the same upstream process.

What each of these attributions shares is not inaccuracy. They are accurate, at least partially. What they share is the functional consequence of closing the clinical conversation. Each one is a translation of “something is happening with my vascular system that I should investigate” into “this is a normal consequence of my circumstances.” The translation is not dishonest. It is expensive.

What Your Urologist Might Not Have Said

If you have sought help for erectile dysfunction, you have likely seen a urologist or a primary care physician and been prescribed a PDE5 inhibitor — sildenafil, tadalafil, or similar. This is appropriate treatment. PDE5 inhibitors work by inhibiting the enzyme that breaks down cGMP, the intracellular messenger that mediates nitric oxide’s effect on smooth muscle relaxation. They improve erectile function in the majority of men with vasculogenic ED and are safe for most patients. They are also, potentially, cardioprotective — the Princeton IV Consensus notes emerging evidence that PDE5 inhibitors may have vasculoprotective effects beyond their primary indication.

What is less commonly communicated in that clinical encounter: the fact that vasculogenic erectile dysfunction is a cardiovascular sentinel event, that it warrants a cardiovascular evaluation alongside the prescription, and that the evaluation should include an ApoB level, an assessment of blood pressure, a fasting glucose, and — in men at low to intermediate cardiovascular risk — consideration of coronary artery calcium scoring.

I do not say this as a criticism of urology. I say it as a cardiologist observing a gap that exists at the specialty interface: the urologist who manages sexual medicine appropriately but is not trained in cardiovascular risk stratification, and the primary care physician or cardiologist who never asks about erectile function because it is not on the cardiovascular risk assessment form.

That gap is where the two-to-five year window gets used up without action.

A 2021 review by Vlachopoulos and colleagues in the Journal of Clinical Medicine framed it this way: erectile dysfunction should be considered a hallmark of cardiovascular disease in men under sixty, and its investigation should trigger a cardiovascular workup as a matter of routine (Vlachopoulos et al. 2021, PMC8161068). Not as an afterthought. As part of the standard of care.

Testosterone in This Picture

I want to address testosterone here because it is the explanation that many men reach for when they experience erectile dysfunction, and the relationship is real but more nuanced than it is usually presented.

Low testosterone — defined clinically as serum total testosterone below approximately 10.4 nmol/L (300 ng/dL) by most U.S. laboratory references — is associated with reduced libido, fatigue, and erectile dysfunction. It is also an independent cardiovascular risk marker: a 2008 prospective study by Laughlin and colleagues in the Journal of Clinical Endocrinology & Metabolism found that men in the lowest testosterone quartile had significantly elevated all-cause and cardiovascular mortality (Laughlin et al. 2008, DOI: 10.1210/jc.2007-1792). Testosterone is not merely a sexual hormone. It is a vascular hormone — it maintains endothelial nitric oxide production, influences lipid metabolism, and affects insulin sensitivity.

However, in the clinical picture of erectile dysfunction as a cardiovascular sentinel event, low testosterone is a co-finding, not the primary mechanism. The artery-size hypothesis holds independently of testosterone levels. Men with normal testosterone can have vasculogenic ED from endothelial dysfunction. Men with low testosterone can have vasculogenic ED as well, with both the testosterone deficiency and the endothelial dysfunction being downstream manifestations of the same upstream process: the cortisol-driven HPA-HPG axis dysregulation, the metabolic syndrome, the chronic physiological load of a man running above his design spec.

The clinical implication: when you are evaluated for erectile dysfunction, testosterone should be measured. But the measurement of testosterone, even if normal, does not close the cardiovascular question. It is one piece of a picture that should include endothelial health, ApoB, blood pressure, and — in appropriate candidates — CAC scoring.

The Clinical Conversation You Need to Have

This section is for the man who has been carrying this information, has already experienced what he knows is probably vasculogenic erectile dysfunction, and has not yet had the specific cardiovascular conversation this clinical picture warrants. Let me give you the words.

The conversation begins with your primary care physician or, ideally, a cardiologist. You can say, specifically: “I’ve been experiencing erectile dysfunction that I think is vascular in origin, and I’ve read that this can be an early cardiovascular marker. I’d like a cardiovascular risk assessment.” That sentence is accurate, is supported by major cardiology society consensus documents, and is sufficient to initiate the appropriate evaluation.

The specific tests that should be part of that evaluation include: ApoB (not just LDL), high-sensitivity CRP (hsCRP), fasting glucose and hemoglobin A1c, blood pressure measured properly (two readings, five minutes apart, seated, without conversation), and — depending on your 10-year cardiovascular risk estimate — a coronary artery calcium score. Testosterone and SHBG should also be measured, as part of a complete hormonal picture.

If your physician dismisses the ED-cardiovascular connection, you have the right to ask them to review the 2013 European Heart Journal paper by Vlachopoulos and colleagues and the 2024 Princeton IV Consensus in Mayo Clinic Proceedings. Both are peer-reviewed, major-journal documents representing the current standard of care for managing erectile dysfunction in the context of cardiovascular risk assessment. You have a right to this conversation.

A 2022 paper by Corona and colleagues in Biomedicines synthesized the mechanistic evidence for the endothelial dysfunction–erectile dysfunction–cardiovascular disease pathway, confirming it as the consensus framework (Corona et al. 2022, PMC9405076). This is not fringe cardiology. It is current cardiology, and your clinical care should reflect it.

The Things That Are Not the Issue

Let me be clear about scope, because the evidence deserves honest framing.

Not all erectile dysfunction is vasculogenic. Neurogenic ED — from spinal cord disease, multiple sclerosis, diabetes-associated neuropathy — carries different clinical implications. Psychogenic ED — anxiety, relationship dynamics, performance pressure — is real and common, particularly in younger men, and does not carry the same vascular signal. Medication-induced ED — from antihypertensives, antidepressants, certain cardiac medications — has a different mechanism. The distinguishing features of vasculogenic ED include: gradual onset over months to years, consistent impairment across situations and partners, loss of nocturnal and morning erections, and presence in the context of other cardiovascular risk factors.

The predictive value of ED as a cardiovascular signal is strongest in men under sixty and attenuates significantly after seventy, where the background prevalence of both ED and cardiovascular disease makes the association less specific. In men under fifty with new-onset, progressive erectile dysfunction, the signal is at its most clinically actionable.

The honest qualifier: the evidence is strong for vasculogenic ED under sixty as a cardiovascular sentinel event. The two-to-five year lead time is an average from observational cohort data, not a fixed biological clock — some men have shorter windows, some longer. The absence of ED does not guarantee the absence of endothelial dysfunction. But the presence of ED in a man in his forties or early fifties who has not had a cardiovascular evaluation is a finding that belongs in a cardiologist’s office.

Clinical Pearl — If you read nothing else in this chapter:

A meta-analysis of multiple prospective cohort studies found that erectile dysfunction independently increases the risk of coronary heart disease by 62%, cardiovascular events by 47%, stroke by 39%, and all-cause mortality by 25%. The word “independently” means this is true after controlling for age, smoking, hypertension, diabetes, and cholesterol. In men between 40 and 49, the hazard ratio for incident coronary artery disease in those who develop ED is approximately 5.0. The two-to-five year window between ED onset and coronary events is an intervention window. The Princeton IV Consensus (2024) now recommends coronary artery calcium scoring as a standard risk stratification step for men with ED at low to intermediate cardiovascular risk. If you have experienced erectile dysfunction and have not had a cardiovascular evaluation, you have a sentinel event that has not yet been investigated (Vlachopoulos et al. 2013, DOI: 10.1093/eurheartj/eht112; Inman et al. 2009, PMC2664580).

A Composite Clinical Portrait

Michael is forty-four. He manages a private equity firm in midtown Manhattan. He came in for an executive physical that his company provides annually — he attends because the company mandates it, not because he has concerns.

He has been taking tadalafil for approximately eighteen months. His primary care physician prescribed it during a visit that ran about twelve minutes; the physician asked about the erectile dysfunction briefly, confirmed it wasn’t bothering him too much, and wrote the prescription. No one ordered an ApoB level. No one performed a cardiac stress test. No one asked about the pattern of onset — which, Michael confirms when I ask, was gradual, beginning roughly two years ago, progressing over about six months from occasional to consistent, not situationally variable. He has no morning erections. He has not mentioned any of this to anyone except the physician who prescribed the medication.

Two years of gradual, progressive, non-situational erectile dysfunction in a man with a blood pressure of 142/92 and a BMI of 27. In cardiovascular terms: at least two years of evolving endothelial dysfunction, now presenting with a blood pressure that has probably been elevated for longer than he realizes.

His ApoB is 118 mg/dL when I order it. His hsCRP is 2.1. His fasting glucose is 104. His CAC score comes back at 87 — early coronary artery calcium, in a forty-four-year-old, indicating atherosclerotic plaque already present and calcifying.

He is, he told me at the beginning of our encounter, basically healthy. He is not basically healthy. He is a man with a sentinel event that bought him a two-to-five year window, and that window is currently at eighteen months. He is also — and I want to say this clearly — a man who can do something about all of this. His window is open. We have his numbers. We know what to do. That is exactly what preventive cardiology is for.

The Permission Paragraph

If you have noticed changes in sexual function and have attributed them to stress, age, or the amount you’ve been drinking — if you’ve been carrying this privately for months or years, in the specific silence reserved for things that feel like admissions — I need you to read this paragraph carefully.

You are not wrong that stress has an effect. You are not wrong that age has an effect. You are wrong that the effect is only those things, and wrong that the explanation closes the clinical question.

What you have been noticing is your vascular system doing precisely what it is designed to do: reporting a problem in the language of the most sensitive vascular territory it has. The penile circulation is your body’s early-warning vascular newspaper, printed in the font of a symptom you didn’t want to investigate. Your body is not betraying you. It is trying to inform you.

You are allowed to receive that information. You are allowed to receive it without shame — there is nothing in the clinical literature that assigns moral weight to vasculogenic erectile dysfunction; it is a hemodynamic finding, not a character assessment. And you are allowed to take it to a physician in the same matter-of-fact register in which you would take an abnormal laboratory value.

What you do next is the conversation this book exists to prepare you for.

What to Do This Week

1. If you have experienced erectile dysfunction — gradual onset, progressive, not situationally variable, present for more than six months — schedule a physician appointment specifically for a cardiovascular risk assessment. The phrase to use: “I’ve read that vasculogenic erectile dysfunction is a cardiovascular sentinel event and I’d like an evaluation.” Bring this chapter. The physician who has not encountered this conversation will benefit from having the evidence framing in hand.

2. Ask your physician to order the following at that appointment or your next one: ApoB (not just LDL), high-sensitivity CRP (hsCRP), fasting glucose or hemoglobin A1c, blood pressure measured properly, and total and free testosterone with SHBG. This is a cardiovascular baseline, not an elaborate workup. It is the minimum required to understand what your vascular system is doing.

3. If your physician dismisses the ED-cardiovascular connection, ask them to review the Vlachopoulos 2013 European Heart Journal paper and the 2024 Princeton IV Consensus. Both are publicly available. You have a right to the conversation this evidence supports.

The penile artery is the signal. The cortisol is the engine. Chapter 4 is about the engine — the stress hormone system that has been running above its design spec for years, and what that overrun does to the inside of your arteries in ways you cannot see and have not been measuring.